Evoke Wealth’s United Therapeutics UTHR Stock Holding History

Evoke Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-582	Closed	-$345K	–	611
2026 Q1	$345K	Buy	582 +39	+7%	+$19.4K	0.01%	506
2025 Q4	$265K	Buy	+543	New	+$253K	﹤0.01%	555
2020 Q3	–	Sell	-6	Closed	-$1K	–	1138
2020 Q2	$1K	Buy	+6	New	+$675	﹤0.01%	1043

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Evoke Wealth's UTHR Position: Q2 2026 in Review

Evoke Wealth sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 582 shares — an estimated $345K sold.

Evoke Wealth first reported a position in UTHR in Q2 2020 and held it in 3 quarters. The position peaked at $345K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Evoke Wealth reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Evoke Wealth sold 582 United Therapeutics shares in Q2 2026, an estimated $345K.
Evoke Wealth first reported a position in United Therapeutics in Q2 2020 and held it in 3 quarters.
Evoke Wealth's United Therapeutics position peaked at $345K in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.